Risk Factors Update Summary

• The total consolidated debt increased from $1 billion to $1.047 billion, impacting financial flexibility.
• The FDA's new Quality Management System Regulation, effective February 2, 2026, may impose additional compliance costs.
• Healthcare reform or cost-cutting measures may adversely affect revenues, potentially leading to lower reimbursements.
• The Inflation Reduction Act introduced a 15% corporate minimum tax on adjusted financial statement income for companies with average adjusted net income exceeding $1 billion.
• The company faces risks from pandemics and public health crises, which could materially impact operations.
• Developments in tax laws, including proposed changes to IRC Section 174, could significantly impact our effective tax rate and financial position.
• Cybersecurity threats are increasing, with potential for significant operational disruptions and reputational harm.
• Sustainability practices are under increasing scrutiny; failure to comply may negatively affect our reputation and business relationships.
• Changes in privacy regulations may impose additional compliance costs, affecting financial condition and operations.
• The introduction of pharmaceuticals for obesity treatment may impact the perceived demand for our products.
• The company is monitoring geopolitical risks globally, which could impact business operations and partnerships.